Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Elevation Oncology Q4 EPS $(0.19) Beats $(0.23) Estimate; Cash, Cash Equivalents And Marketable Securities And Approximately $17M In Net Proceeds Raised Under Its ATM Facility Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025

Author: Benzinga Newsdesk | March 06, 2024 08:36am
Elevation Oncology (NASDAQ:ELEV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 76.83 percent increase over losses of $(0.82) per share from the same period last year.

Posted In: ELEV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist